Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The investigators primarily aim to observe the number of relapses from initiation of baricitinib treatment.
The secondary outcomes are to determine: The safety profile of baricitinib in participants with NMO and whether baricitinib improves Expanded Disability Status Scale (EDSS), et al.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Qiang Liu, M.D.,Ph.D.
- Phone Number: +86 15022439149
- Email: qliu@tmu.edu.cn
Study Locations
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300052
- Tianjin Medical University General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients ≥ 18 years old;
- Diagnosis of NMO or NMO spectrum disorder according to the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria;
- Clinical evidence of either at least one relapse requiring rescue therapy (intravenous corticosteroids, intravenous immunoglobulin, plasma exchange or a combination of these therapies) in the year before screening or at least two relapses requiring rescue therapy in the 2 years before screening;
- Expanded disability status scale (EDSS) score ≤ 6.0;
- Patients were seropositive for AQP4-IgG;
- Able and willing to give written informed consent and comply with the requirements of the study protocol.
Exclusion Criteria:
- Current evidence or known history of clinically significant infection (Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, Hepatitis viruses, Syphilis, etc);
- Participation in another interventional study within the last 3 months;
- Tumor disease currently or within the last 5 years;
- Pregnancy, breastfeeding, or child-bearing potential during the course of the study;
- Patients with clinically relevant heart, liver, kidney or bone marrow dysfunction;
- History of venous thromboembolism (VTE), or are considered at high risk for VTE by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Baricitinib
Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 96.
|
Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 96.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of relapses
Time Frame: From baseline to 96 weeks
|
A relapse was defined as new-onset neurological symptoms or worsening of existing neurological function (vision loss, limb weakness or sensory symptoms, or bladder or bowel dysfunction) lasting more than 24 h, not attributable to an identifiable cause such as intercurrent infection, and preceded by at least 30 days of clinical stability.
|
From baseline to 96 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in EDSS scores
Time Frame: Changes in EDSS from baseline to 96 weeks
|
The Expanded Disability Status Scale (EDSS) is a rating system that is frequently used for classifying and standardizing the severity and progression.
EDSS ranges from 0 to 10.
|
Changes in EDSS from baseline to 96 weeks
|
|
Changes in the number of new and/or enlarging lesions on T2-weighted imaging (T2WI) and gadolinium-enhancing lesions on T1-weighted imaging (T1WI).
Time Frame: From baseline to 96 weeks
|
The total number of new and/or enlarging lesions on T2-weighted imaging (T2WI) and gadolinium-enhancing lesions on T1-weighted imaging (T1WI) for all participants was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96
|
From baseline to 96 weeks
|
|
Changes in the number of peripheral blood B cell subsets
Time Frame: From baseline to 96 weeks
|
Compare peripheral blood plasma cells before and two year after initial intervention
|
From baseline to 96 weeks
|
|
Changes in serum AQP4-IgG titer
Time Frame: From baseline to 96 weeks
|
Compare serum AQP4-IgG titers before and two year after initial intervention
|
From baseline to 96 weeks
|
|
Incidence of treatment-emergent adverse events [safety and tolerability]
Time Frame: From baseline to 96 weeks
|
Adverse events related to baricitinib are recorded
|
From baseline to 96 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Qiang Liu, M.D.,PhD, Tianjin Medical University General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB2023-YX-012-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.